ProShare Advisors
GRNA

ProShare Advisors’s GreenLight Biosciences Holdings, PBC Common Stock GRNA Stock Holding History

ProShare Advisors’s Portfolio GRNA Stock Details GRNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-21,028
Closed -$9.09K – 1941
2023
Q1 		$9.09K Sell
21,028
-3,009
-13% -$2.31K ﹤0.01% 1769
2022
Q4 		$28.4K Buy
+24,037
New +$39.1K ﹤0.01% 1789

Other funds holding GRNA

CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
CGC
Continental Grain Company New York $366M AUM 0.18% 1-Year Est. Return
TCM
Tao Capital Management San Francisco, California $119M AUM 87.46% 1-Year Est. Return
Hudson Bay Capital Management
Hudson Bay Capital Management Stamford, Connecticut $29B AUM 30.2% 1-Year Est. Return
BOTOTLSJU
Board of Trustees of The Leland Stanford Junior University Redwood City, California $849M AUM 55.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BNP Paribas Asset Management
BNP Paribas Asset Management Paris, France $86.1B AUM 29.11% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
CM
Crystalline Management Montreal, Quebec, Canada $112M AUM 21.13% 1-Year Est. Return

ProShare Advisors's GRNA Position: Q2 2023 in Review

ProShare Advisors sold out of GreenLight Biosciences Holdings, PBC Common Stock (GRNA) in Q2 2023, closing a stake of 21,028 shares — an estimated $9.09K sold.

ProShare Advisors first reported a position in GRNA in Q4 2022 and held it in 2 quarters. The position peaked at $28.4K in Q4 2022. 48 funds tracked by Wall St. Rank hold GRNA as of Q2 2023.

  • ProShare Advisors reported no remaining GreenLight Biosciences Holdings, PBC Common Stock position as of Q2 2023 after selling out during the quarter.
  • ProShare Advisors sold 21,028 GreenLight Biosciences Holdings, PBC Common Stock shares in Q2 2023, an estimated $9.09K.
  • ProShare Advisors first reported a position in GreenLight Biosciences Holdings, PBC Common Stock in Q4 2022 and held it in 2 quarters.
  • ProShare Advisors's GreenLight Biosciences Holdings, PBC Common Stock position peaked at $28.4K in Q4 2022.
  • 48 funds tracked by Wall St. Rank held GreenLight Biosciences Holdings, PBC Common Stock as of Q2 2023.

Based on ProShare Advisors's 13F filing for Q2 2023, filed 10 Aug 2023.